The Washington Manual Subspecialty Consult Series is designed to provide quick access to the essential information needed to evaluate a patient on a subspecialty consult service. The Washington Manual of Hematology and Oncology subspecialty consult has been completely reviewed, revised, and follows the bulleted format and template of The Washington Manual of Medical Therapeutics, 33/e to allow for quick,readily accessible information. This edition has been...
More DescriptionThe Washington Manual Subspecialty Consult Series is designed to provide quick access to the essential information needed to evaluate a patient on a subspecialty consult service. The Washington Manual of Hematology and Oncology subspecialty consult has been completely reviewed, revised, and follows the bulleted format and template of The Washington Manual of Medical Therapeutics, 33/e to allow for quick,readily accessible information.
This edition has been updated to include new standards in the treatment of malignancies and hematologic disorders, mechanisms of action of new therapeutic agents, and the current use of molecular prognostic factors. The information in each chapter is now presented in a consistent format, with important references cited.
The Manual is a practical reference for fellows, residents, and medical students rotating on hematology and oncology subspecialty services. Most of the authors are hematology-oncology fellows or internal medicine residents, the physicians who have recent experience with the issues and questions that arise in the course of training in these subspecialties. Primary care practitioners and other health care professionals also will find this manual useful as a quick reference source in hematology and oncology.
Features include:
- New, templated format same as The Washington University Medical Therapeutics, 33e
- Contains synopsis of symptoms, signs, and problems encountered in their daily workflow in a bulleted format for quick salient points
- Includes new standards in the treatment of malignancies and hematologic disorders, mechanisms of action of new therapeutic agents, and the current use of molecular prognostic factors